Dr. Howard Scher discusses MDV3100, a novel oral androgen receptor antagonist. The agent is under study for the treament of castrate-resistant prostate cancer. Patrice Wendling of the Global Medical News Network (GMNN) reports from the annual Genitourinary Cancers Symposium.